Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
07:00am, Tuesday, 23'rd Jan 2024
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
12:02pm, Friday, 05'th Jan 2024
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates.
Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?
09:46am, Friday, 05'th Jan 2024
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
2 Biotech Stocks You Can Buy and Hold for the Next Decade
08:45am, Tuesday, 02'nd Jan 2024
AbbVie's recent major patent cliff won't kill its returns throughout the next decade. Axsome Therapeutics is gaining in prominence thanks to an exciting late-stage pipeline.
Axsome: Show Me Another Company With Such A Stack Of Catalysts
09:28am, Sunday, 24'th Dec 2023
Axsome Therapeutics has consistently beaten revenue estimates since the approval of Auvelity, indicating better-than-expected performance. While the company's expenses, particularly in commercial acti
3 Biotech Stocks That Could Be Millionaire Makers
05:30am, Wednesday, 22'nd Nov 2023
There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies a
3 Growth Stocks to Buy Right Now Without Any Hesitation
06:50am, Saturday, 11'th Nov 2023
AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
12:47pm, Tuesday, 07'th Nov 2023
Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.
Riding the Wave: 3 Stocks That Can 10X by 2025
09:23pm, Monday, 30'th Oct 2023
It's the dream of every investor to uncover stocks with the potential to grow tenfold within a short span. While it may sound like a lofty goal, the article reveals that it's not just a pipe dream.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:18am, Monday, 30'th Oct 2023
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Update: Buy At Dips And Hold Forever
06:11am, Monday, 16'th Oct 2023
Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quarter. Auvelity offers rapid onset of symptom improv
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
07:00am, Tuesday, 10'th Oct 2023
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time
2 Top Biotech Stocks to Buy in October
05:30am, Tuesday, 03'rd Oct 2023
Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.
Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?
12:47pm, Wednesday, 06'th Sep 2023
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
05:52am, Saturday, 19'th Aug 2023
Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over time.
